[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xi'an No.3 Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":163},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,98,120,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100603668","phase-1-allogeneic-ucb-derived-dual-targeting-bcmacd19-car-t-for-relapsedrefractory-multiple-myeloma-100603668",false,"NCT07139509","Allogeneic UCB-derived, Dual-targeting BCMA\u002FCD19 CAR-T for Relapsed\u002FRefractory Multiple Myeloma","Clinical Study on the Safety and Tolerability of Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA\u002FCD19 CAR-T Therapy for Relapsed\u002FRefractory Multiple Myeloma","UCAR-T_MM-XA","Inclusion Criteria:\n\n* 1.Aged 18 to 75 years (inclusive of boundary values), with no limitation on gender;\n* 2.Diagnosed with multiple myeloma in accordance with the \"Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)\" :\n\n  1. Bone marrow monoclonal plasma cell percentage ≥10% and\u002For histopathological evidence of plasmacytoma; and presence of at least one of the following SLiM CRAB features:\n\n     SLiM refers to:\n     * S: Bone marrow monoclonal plasma cell percentage ≥60%;\n     * Li: Ratio of involved to uninvolved serum free light chain ≥100 (with the involved light chain value being at least ≥100 mg\u002FL);\n     * M: MRI detection of \\>1 focal bone lesion larger than 5 mm.\n\n     CRAB refers to:\n     * C: Corrected serum calcium \\>2.75 mmol\u002FL \\[Corrected serum calcium (mmol\u002FL) = serum total calcium (mmol\u002FL) - 0.025×serum albumin concentration (g\u002FL) + 1.0 (mmol\u002FL), or corrected serum calcium (mg\u002Fdl) = serum total calcium (mg\u002Fdl) - serum albumin concentration (g\u002FL) + 4.0 (mg\u002Fdl)\\];\n     * R: Renal insufficiency (creatinine clearance \\\u003C40 ml\u002Fmin or serum creatinine \\>177 μmol\u002FL);\n     * A: Anemia (hemoglobin \\\u003C lower limit of normal by 20 g\u002FL or \\\u003C100 g\u002FL);\n     * B: Lytic bone lesions, demonstrated by radiographic imaging (X-ray, CT, MRI, or PET-CT) showing one or more lytic bone lesions.\n  2. Definition of relapsed\u002Frefractory multiple myeloma:\n\n     * Must have received at least three therapeutic regimens (The induction and maintenance therapies associated with hematopoietic stem cell transplantation, whether one or both were performed, are considered as one therapeutic regimen);\n     * Must have been treated with a proteasome inhibitor, an immunomodulatory agent, or an anti-CD38 antibody;\n     * Must be refractory to the last therapeutic regimen \\[refractory is defined as disease progression documented during or within 60 days after completion of the last anti-multiple myeloma therapeutic regimen (based on the last dose of the drug)\\].\n* 3.Presence of at least one measurable lesion, meeting at least one of the following criteria:\n\n  * Serum M protein ≥0.5 g\u002FdL;\n  * Urine M protein ≥200 mg\u002F24 hours;\n  * Serum free light chain (FLC) assay: involved FLC level ≥10 mg\u002FdL (100 mg\u002FL), provided that the serum FLC ratio is abnormal;\n  * Biopsy-proven evaluable plasmacytoma;\n  * Bone marrow plasma cells constituting \\>30% of total bone marrow cells;\n* 4.Negative for Donor Specific Antibody (DSA);\n* 5.The most recent assessment during the screening period indicates sufficient organ function, including renal and hepatic function, defined as:\n\n  * Creatinine clearance rate ≥60 mL\u002Fmin (calculated according to the Cockcroft-Gault formula);\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (upper limit of normal);\n  * Total bilirubin ≤1.5×ULN (for participants with a history of Gilbert's syndrome, total bilirubin ≤2.5×ULN).\n* 6.Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment. In this study, women of childbearing potential, their male partners with reproductive potential, and their partners must use effective contraception from the screening period until 12 months after UC503 administration. Women who are not of childbearing potential are defined as those who are at least 1 year postmenopausal or have documented infertility (congenital or acquired);\n* 7.Written informed consent obtained before the initiation of any study-specific procedures.\n\nExclusion Criteria:\n\n* 1.Participants meeting any of the following criteria are not eligible for enrollment in this study:\n* 2.Lactating women;\n* 3.Unwillingness to undergo follow-up for 15 years;\n* 4.Poor compliance with the study procedures;\n* 5.Individuals under legal guardianship or conservatorship;\n* 6.with a history of ≥Grade 4 CRS or neurotoxicity in previous CAR-T therapy ;\n* 7.Within 5 half-lives of prior anti-MM therapies (including approved therapies and other investigational drugs) before enrollment;\n* 8.Disease progression after debulking therapy;\n* 9.Active central nervous system (CNS) abnormalities or history of irreversible severe CNS toxicity from prior MM treatment leading to CNS organic lesions or CNS dysfunction;\n* 10.Radioimmunotherapy or radiotherapy within 8 weeks before enrollment;\n* 11.Hematopoietic stem cell transplantation (HSCT) within 3 months before screening, donor lymphocyte infusion within 6 weeks before screening; patients who have undergone autologous stem cell transplantation within 100 days; patients who have undergone solid organ transplantation;\n* 12.Active acute or chronic graft-versus-host disease (GvHD) requiring systemic therapy within 4 weeks before UC503 cells infusion;\n* 13.Patients with autoimmune diseases who are unable to discontinue systemic immunosuppressive therapy;\n* 14.Patients currently receiving or having received high-dose (total dose of 60 mg dexamethasone or equivalent other corticosteroid) systemic corticosteroid therapy within 4 weeks before lymphodepletion;\n* 15.Known hypersensitivity to UCAR-T or any of its components;\n* 16.Any known uncontrolled cardiovascular disease within 6 months before enrollment, or any of the following conditions: ≥Grade 2 ventricular or atrial arrhythmias, ≥Grade 2 bradycardia, myocardial infarction, severe\u002Funstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, poorly controlled hypertension with standard medications. Or left ventricular ejection fraction (LVEF) \\\u003C 45% as assessed by echocardiogram or multigated acquisition scan (MUGA) at screening;\n* 17.Any known uncontrolled pulmonary disease within 6 months before enrollment, or any of the following conditions: pulmonary embolism, chronic obstructive pulmonary disease, history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia on chest CT scan at screening. A history of radiation pneumonitis\u002Ffibrosis within the radiation field is allowed, as well as symptomatic or poorly controlled interstitial lung disease, clinically significant pulmonary function abnormalities;\n* 18.History of hypertensive crisis or hypertensive encephalopathy within 3 months before screening;\n* 19.At enrollment, active bacterial, fungal, protozoal, or viral infections that are not effectively controlled despite adequate treatment, and positive blood cultures within 7 days before enrollment;\n* 20.Undergone any major surgery within 3 months before screening;\n* 21.Received any live-attenuated vaccine within 4 weeks before screening;\n* 22.Any abnormal findings, medical conditions, or laboratory test results during the screening period that the investigator deems may jeopardize patient safety;\n* 23.Any planned medical or surgical treatment that may interfere with the normal conduct of the study;\n* 24.Presence of another malignancy within 2 years before screening (excluding in situ basal or squamous cervical cancer or cutaneous basal cell carcinoma);\n* 25.Patient's psychiatric condition that prevents understanding of the nature, scope, and potential consequences of the study, and\u002For unwillingness to cooperate;\n* 26.At enrollment, positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal range; positive for hepatitis C virus (HCV) antibody with peripheral blood HCV RNA titer greater than the normal range; positive for human immunodeficiency virus (HIV) antibody; positive for human T-cell leukemia virus (HTLV) antibody; positive for Treponema pallidum antibody; positive for cytomegalovirus (CMV) DNA;\n* 27.Contraindications to any drugs that may be used, including lymphodepleting agents such as fludarabine and cyclophosphamide, or agents maybe used for managing adverse events such as tocilizumab.","ALL","18 Years","75 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this clinical trial is to learn if allogeneic cord blood-derived CAR-T cell drug works to treat Multiple Myeloma (MM) including Bone-related extramedullary (EMB) disease and extramedullary extraosseous disease(EME) in adults. It will also learn about the safety of the allogeneic cord blood-derived CAR-T cell drug. The main questions it aims to answer are:\n\n1. What adverse events occur and the incidence rate of DLTs within 28 days and UCAR-T-related AEs within 28 days after the allogeneic cord blood-derived CAR-T cell injection for multiple myeloma (MM)?\n2. Which dose level is the optimal biological dose (OBD)?\n3. What is the overall responserate (ORR), including stringent complete response (sCR), completeresponse (CR),very good partial response (VGPR), partial response (PR), minimal Response (MR) and DOR, PFS, RFS, OS?\n\nParticipants will:\n\n1. be pretreated with FC regimen, fludarabine (30mg\u002Fm²\u002Fd, days -5, -4, and -3) and cyclophosphamide (300\\~500 mg\u002Fm²\u002Fd, day -5,-4, and -3).\n2. rest for 2 days on Day-2 and Day-1. Tumor burden should be re-evaluated and chemotherapy side effects assessment.\n3. receive allogeneic cord blood-derived CAR-T cells infusion\n4. Visit the clinic at D28, 1 month, 2 months, 3 months, 4 months, 6 months, 9 months and 1 year after CAR-T cells infusion.",[28],"Relapsed\u002FRefractory Multiple Myeloma(MM)",[30,31,32],"allogeneic CAR-T","umbilical cord blood-derived","relapsed\u002Frefractory multiple myeloma","RECRUITING","2025-11-19",{"date":36,"type":37},"2025-11-25","ACTUAL",{"date":39,"type":37},"2024-10-03",{"date":41,"type":22},"2028-12-30",{"name":43,"class":44},"Xi'an No.3 Hospital","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100546117","efficacy-of-acupuncture-for-the-treatment-of-parkinsons-disease-related-constipation-100546117","NCT06390761","Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation","Acupuncture for the Treatment of Parkinson's Disease Related Constipation","AFPDC","Inclusion Criteria:\n\n1. A diagnosis of PD (according to the Movement Disorder Society's revised clinical diagnostic criteria for Parkinson's disease in 2015) and functional constipation (according to the Rome IV diagnostic criteria) ;\n2. Age between 35 and 80 years;\n3. Hoehn-Yahr grade ≤ 3;\n4. No medications taken within 2 weeks that may affect gastrointestinal function (such as prucalopride and probiotics);\n5. No anticipation in other clinical trials within 1 month;\n6. Voluntary engagement in this study, ability to sign the informed consent, and cooperation in the completion of the bowel diary and scale filling.\n\nExclusion Criteria:\n\n1. Organic lesions of the digestive system (such as intestinal adhesions, obstructions, tumors, or malformations in the gastrointestinal tract);\n2. A history of abdominal or anorectal surgery that may affect intestinal transit, systemic diseases that may affect the dynamics of the digestive tract (such as diabetes and hyperthyroidism);\n3. Serious life-threatening diseases (such as severe cardiovascular diseases and malignant tumors);\n4. Skin lesions that were inappropriate for needling, the viscose allergy that prevented acupuncture device attachment;\n5. Pregnant or lactating women.","35 Years","80 Years",{"count":57,"type":22},60,[59],"NA","The purpose of the study is to evaluate the efficacy of acupuncture in treating Parkinson's disease related constipation (PDC). In the randomized controlled clinical trial study, patients meeting the criteria for inclusion will be randomly enrolled and divided into two groups in a 1:1 ratio: the acupuncture group and the sham acupuncture group. The intervention is going to be executed using the acupoints EX-HN1（Sishencong),LI4 (Hegu),ST25 (Tianshu),ST37(Shangjuxu),ST36(Zusanli),ST44 (Neiting), ST44 (Taichong), SP6 (Sanyinjiao) and CV4 (Shuangyuan).The acupuncture needles will be inserted to a depth of 0.8 to 1 cm in the acupuncture group. The sham acupuncture group's needles will be inserted to a depth of 0.2 to 0.3 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points. During the study, researchers will observe changes in complete spontaneous bowel movements (CSBMs), Constipation Symptom and Efficacy Assessment Scale (CSEAS) (including the six dimensions of difficulty, Bristol, time, incompleteness, frequency,and bloating), the Patient-Assessment of Constipation Quality of Life questionnaire (PAC-QOL), and the Unified Parkinson's Disease Rating Scale (UPDRS) at baseline (week 0), post-treatment (week 4), and follow-up (week 12).Colonic transit time measurement and conventional anorectal manometry were evaluated at the above time points.",[62,63,64,65],"Parkinson Disease","Constipation","Non-motor Symptom","Randomized Controlled Trial","2024-04-30",{"date":68,"type":37},"2024-05-02",{"date":66,"type":22},{"date":71,"type":22},"2027-12-30",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100471907","application-of-standardized-green-channel-treatment-system-for-ischemic-stroke-in-xi-an-100471907","NCT05424978","Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an","Asgctsis","Inclusion Criteria:\n\n* 18 years old;\n* Consistent with the diagnosis of acute ischemic stroke;\n* 24 hours from onset to enrollment;\n* Informed consent\n\nExclusion Criteria:\n\n* Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);\n* Stroke patients caused by brain tumor, brain trauma and blood diseases;\n* Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;\n* Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;\n* Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);\n* Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;\n* Other diseases that limit neurological function evaluation or affect patient follow-up;\n* A woman planning to be pregnant or breastfeeding;\n* Currently participating in other clinical trials;\n* Refuse to participate in the registration of investigators","100 Years",{"count":82,"type":22},3600,"90 Days","OBSERVATIONAL","Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.",[87,88,89],"Acute Ischemic Stroke","Thrombolysis","Endovascular Treatment","2024-01-24",{"date":92,"type":37},"2024-01-26",{"date":94,"type":37},"2022-06-01",{"date":96,"type":22},"2028-07-31",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100516171","head-acupuncture-treat-residual-symptoms-after-canalith-repositioning-procedure-for-bppv-100516171","NCT06001047","Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV","Effect of Head Acupuncture on Residual Symptoms After Canalith Repositioning Procedure for Benign Paroxysmal Positional Vertigo: a Single-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. According to the diagnostic criteria and therapeutic efficacy evaluation for benign paroxysmal positional vertigo (BPPV) formulated by the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association, the patient was confirmed as having BPPV and the repositioning maneuver was successful.\n2. After the maneuver, the patient's clinical symptoms were relieved, with no sense of rotation or dizziness, but residual symptoms such as discomfort and unsteady gait persisted.\n3. There were no obvious communication barriers or visual impairments.\n4. The patient and their family members agreed to the treatment plan.\n\nExclusion Criteria:\n\n* Patients with other ear diseases, history of head trauma or surgery;\n\n  * Patients who are weak and unable to tolerate, pregnant women;\n\n    * Patients who have undergone vestibular rehabilitation training before this treatment; ④ Patients with joint diseases that affect balance and walking; ⑤ Patients with a history of brain organic diseases (such as tumors, stroke, cerebral hemorrhage) or severe neurological diseases; ⑥ Patients with incomplete data or who withdraw from treatment midway.","65 Years",{"count":107,"type":22},120,[59],"Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder, and currently, manual repositioning techniques are often used for treatment. However, up to 30%-50% of patients may experience residual symptoms such as non-rotational dizziness, heaviness, instability, and emotional disturbances even after successful repositioning, which significantly impacts their daily functioning and quality of life. Electroacupuncture therapy has been proven to be an effective treatment for dizziness and has been applied to various vestibular disorder patients. However, the efficacy of electroacupuncture on the residual effects of successfully repositioned BPPV patients remains unclear. This study aims to explore the effectiveness of three regimens: electroacupuncture, betahistine in patients with residual symptoms after successful manual repositioning.",[111],"Benign Paroxysmal Positional Vertigo","2023-12-08",{"date":114,"type":37},"2023-12-15",{"date":116,"type":37},"2023-11-01",{"date":118,"type":22},"2026-11-01",{"name":43,"class":44},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100332383","a-new-parameter-derived-from-dsa-to-evaluate-cerebral-perfusion-100332383","NCT03607565","A New Parameter Derived From DSA to Evaluate Cerebral Perfusion","The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia","Inclusion Criteria:\n\n1. Cerebral ischemia\n2. patients undergone DSA\n\nExclusion Criteria:\n\n1.cerebral hemorrhage",{"count":128,"type":22},30000,"This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.",[131],"Cerebral Ischemia","2023-08-31",{"date":134,"type":37},"2023-09-01",{"date":136,"type":37},"2018-07-15",{"date":138,"type":22},"2038-07-15",{"name":43,"class":44},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100482365","efficacy-and-safety-of-head-acupuncture-after-mechanical-thrombectomy-for-acute-ischemic-stroke-100482365","NCT05561088","Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke","A Single-center, Prospective, Randomized, Controlled Study of Mechanical Thrombectomy Followed by Acupuncture for Acute Ischemic Stroke","HEALTH","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients with acute ischemic stroke who received endovascular treatment within 24 hours of onset;\n* 6 \\\u003C NIHSS ≤25;\n* ASPECT score ≥6 points;\n* Signed Informed consent.\n\nExclusion Criteria:\n\n* CT or brain MRI confirmed intracranial tumor and intracranial hemorrhage;\n* Contraindications of contrast media;\n* Dementia or mental illness，unable to cooperate with treatment and follow-up;\n* The expected survival time was less than 3 months;\n* Women who are pregnant, planning to become pregnant or breastfeeding;\n* Currently participating in other clinical trials.",{"count":149,"type":22},272,[59],"To evaluate the efficacy and safety of head acupuncture combined with endovascular therapy for cerebral infarction compared with endovascular therapy alone",[153,87,154],"Acupuncture","Mechanical Thrombectomy","2023-05-11",{"date":157,"type":37},"2023-05-12",{"date":159,"type":37},"2023-04-27",{"date":161,"type":22},"2028-10-31",{"name":43,"class":44},""]